Herd Protection against Meningococcal Disease through Vaccination

被引：23

作者：

Clark, Stephen A. ^{[1
]}

Borrow, Ray ^{[1
]}

机构：

[1] Publ Hlth England, Meningococcal Reference Unit, Natl Infect Serv, Manchester M13 9WL, Lancs, England

来源：

MICROORGANISMS | 2020年 / 8卷 / 11期

关键词：

Neisseria meningitidis; meningococcal infection; meningococcal incidence; invasive meningococcal disease (IMD); IMD epidemiology; meningococcal vaccine; meningococcal vaccination; AFRICAN MENINGITIS BELT; MUCOSAL IMMUNE-RESPONSES; C CONJUGATE VACCINE; SEROGROUP-B; GROUP-A; POLYSACCHARIDE VACCINES; NEISSERIA-MENINGITIDIS; CAPSULAR POLYSACCHARIDE; EPIDEMIOLOGIC IMPACT; UNIVERSITY-STUDENTS;

D O I：

10.3390/microorganisms8111675

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Reduction in the transmission of Neisseria meningitidis within a population results in fewer invasive disease cases. Vaccination with meningococcal vaccines composed of high weight capsular polysaccharide without carrier proteins has minimal effect against carriage or the acquisition of carriage. Conjugate vaccines, however, elicit an enhanced immune response which serves to reduce carriage acquisition and hinder onwards transmission. Since the 1990s, several meningococcal conjugate vaccines have been developed and, when used in age groups associated with higher carriage, they have been shown to provide indirect protection to unvaccinated cohorts. This herd protective effect is important in enhancing the efficiency and impact of vaccination. Studies are ongoing to assess the effect of protein-based group B vaccines on carriage; however, current data cast doubt on their ability to reduce transmission.

引用

页码：1 / 16

页数：16

共 97 条

[71] Carriage Rate and Effects of Vaccination after Outbreaks of Serogroup C Meningococcal Disease, Brazil, 2010 [J].

Palazzi Safadi, Marco Aurelio ;

Marques Pinto Carvalhanas, Telma Regina ;

de Lemos, Ana Paula ;

Outeiro Gorla, Maria Cecilia ;

Salgado, Maristela ;

Fukasawa, Lucila O. ;

Goncalves, Maria Gisele ;

Higa, Fabio ;

Cunto Brandileone, Maria Cristina ;

Sacchi, Claudio Tavares ;

Ribeiro, Ana Freitas ;

Sato, Helena Keico ;

Bricks, Lucia Ferro ;

de Moraes, Jose Cassio .

EMERGING INFECTIOUS DISEASES, 2014, 20 (05) :806-811

[72] Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study [J].

Parikh, Sydel R. ;

Andrews, Nick J. ;

Beebeejaun, Kazim ;

Campbell, Helen ;

Ribeiro, Sonia ;

Ward, Charlotte ;

White, Joanne M. ;

Borrow, Ray ;

Ramsay, Mary E. ;

Ladhani, Shamez N. .

LANCET, 2016, 388 (10061) :2775-2782

[73] From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine [J].

Perez, John L. ;

Absalon, Judith ;

Beeslaar, Johannes ;

Balmer, Paul ;

Jansen, Kathrin U. ;

Jones, Thomas R. ;

Harris, Shannon ;

York, Laura J. ;

Jiang, Qin ;

Radley, David ;

Anderson, Annaliesa S. ;

Crowther, Graham ;

Eiden, Joseph J. .

EXPERT REVIEW OF VACCINES, 2018, 17 (06) :461-477

[74] Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland [J].

Perkins, BA ;

Jonsdottir, K ;

Briem, H ;

Griffiths, E ;

Plikaytis, BD ;

Hoiby, EA ;

Rosenqvist, E ;

Holst, J ;

Nokleby, H ;

Sotolongo, F ;

Sierra, G ;

Campa, HC ;

Carlone, GM ;

Williams, D ;

Dykes, J ;

Kapczynski, D ;

Tikhomirov, E ;

Wenger, JD ;

Broome, CV .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (03) :683-691

[75] Development of natural immunity to Neisseria meningitidis [J].

Pollard, AJ ;

Frasch, C .

VACCINE, 2001, 19 (11-12) :1327-1346

[76] Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis [J].

Ramsay, ME ;

Andrews, NJ ;

Trotter, CL ;

Kaczmarski, EB ;

Miller, E .

BRITISH MEDICAL JOURNAL, 2003, 326 (7385) :365-366

[77] Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial [J].

Read, Robert C. ;

Baxter, David ;

Chadwick, David R. ;

Faust, Saul N. ;

Finn, Adam ;

Gordon, Stephen B. ;

Heath, Paul T. ;

Lewis, David J. M. ;

Pollard, Andrew J. ;

Turner, David P. J. ;

Bazaz, Rohit ;

Ganguli, Amitava ;

Havelock, Tom ;

Neal, Keith R. ;

Okike, Ifeanyichukwu O. ;

Morales-Aza, Begonia ;

Patel, Kamlesh ;

Snape, Matthew D. ;

Williams, John ;

Gilchrist, Stefanie ;

Gray, Steve J. ;

Maiden, Martin C. J. ;

Toneatto, Daniela ;

Wang, Huajun ;

McCarthy, Maggie ;

Dull, Peter M. ;

Borrow, Ray .

LANCET, 2014, 384 (9960) :2123-2131

[78] Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain [J].

Ruiz-Montero, Rafael ;

Epstein, David ;

Guzman Herrador, Bernardo ;

Espin Balbino, Jaime .

GACETA SANITARIA, 2020, 34 (04) :318-325

[79] ANTI-INFLAMMATORY ACTIVITY OF HUMAN-IGA ANTIBODIES AND THEIR FAB-ALPHA FRAGMENTS - INHIBITION OF IGG-MEDIATED COMPLEMENT ACTIVATION [J].

RUSSELL, MW ;

REINHOLDT, J ;

KILIAN, M .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1989, 19 (12) :2243-2249

[80] The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012 [J].

Sadarangani, Manish ;

Scheifele, David W. ;

Halperin, Scott A. ;

Vaudry, Wendy ;

Le Saux, Nicole ;

Tsang, Raymond ;

Bettinger, Julie A. .

CLINICAL INFECTIOUS DISEASES, 2014, 59 (09) :1208-1215

← 1 2 3 4 5 6 7 8 9 10 →